1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Meningioma Global Clinical Trials Review, H1, 2016

Meningioma Global Clinical Trials Review, H1, 2016

  • June 2016
  • -
  • Global Data
  • -
  • 83 pages

Meningioma Global Clinical Trials Review, H1, 2016

Summary

GlobalData's clinical trial report, “Meningioma Global Clinical Trials Review, H1, 2016" provides an overview of Meningioma clinical trials scenario. This report provides top line data relating to the clinical trials on Meningioma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Meningioma Global Clinical Trials Review, H1, 2016
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Report Guidance 4
Clinical Trials by Region 5
Clinical Trials and Average Enrollment by Country 6
Top Countries Contributing to Clinical Trials in Asia-Pacific 8
Top Five Countries Contributing to Clinical Trials in Europe 9
Top Countries Contributing to Clinical Trials in North America 10
Top Countries Contributing to Clinical Trials in Central and South America 11
Clinical Trials by G7 Countries: Proportion of Meningioma to Oncology Clinical Trials 12
Clinical Trials by Phase in G7 Countries 13
Clinical Trials in G7 Countries by Trial Status 14
Clinical Trials by E7 Countries: Proportion of Meningioma to Oncology Clinical Trials 15
Clinical Trials by Phase 16
In Progress Trials by Phase 17
Clinical Trials by Trial Status 18
Clinical Trials by End Point Status 19
Subjects Recruited Over a Period of Time 20
Clinical Trials by Sponsor Type 21
Prominent Sponsors 22
Top Companies Participating in Meningioma Therapeutics Clinical Trials 23
Prominent Drugs 24
Clinical Trial Profile Snapshots 25
Appendix 80
Abbreviations 80
Definitions 80
Research Methodology 81
Secondary Research 81
About GlobalData 82
Contact Us 82
Disclaimer 82
Source 83

List of Tables
Meningioma Therapeutics, Global, Clinical Trials by Region, 2016* 5
Meningioma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 6
Meningioma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 7
Meningioma Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2016* 8
Meningioma Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 9
Meningioma Therapeutics Clinical Trials, North America, Top Countries, 2016* 10
Meningioma Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 11
Proportion of Meningioma to Oncology Clinical Trials, G7 Countries (%), 2016* 12
Meningioma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 13
Meningioma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 14
Proportion of Meningioma to Oncology Clinical Trials, E7 Countries (%), 2016* 15
Meningioma Therapeutics, Global, Clinical Trials by Phase, 2016* 16
Meningioma Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 17
Meningioma Therapeutics, Global, Clinical Trials by Trial Status, 2016* 18
Meningioma Therapeutics Clinical Trials, Global, by End Point Status, 2016* 19
Meningioma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 20
Meningioma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 21
Meningioma Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 22
Meningioma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 23
Meningioma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 24

List of Figures
Meningioma Therapeutics, Global, Clinical Trials by Region (%), 2016* 5
Meningioma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 6
Meningioma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 7
Meningioma Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2016* 8
Meningioma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 9
Meningioma Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 10
Meningioma Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016* 11
Proportion of Meningioma to Oncology Clinical Trials, G7 Countries (%), 2016* 12
Meningioma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 13
Meningioma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 14
Proportion of Meningioma to Oncology Clinical Trials, E7 Countries (%), 2016* 15
Meningioma Therapeutics, Global, Clinical Trials by Phase (%), 2016* 16
Meningioma Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 17
Meningioma Therapeutics, Global, Clinical Trials by Trial Status, 2016* 18
Meningioma Therapeutics Clinical Trials, Global, by End Point Status, 2016* 19
Meningioma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 20
Meningioma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 21
Meningioma Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 22
Meningioma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 23
Meningioma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 24
GlobalData Methodology 81

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Brain Cancer: Analytical Tool

Brain Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Glioblastoma Multiforme-Market Insights, Epidemiology and Market Forecast-2023

Glioblastoma Multiforme-Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Glioblastoma Multiforme - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...


Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in the US

  • November 2016
    74 pages
  • Cancer  

  • United States  

View report >

Cancer Statistics and Therapy Market in the US - Forecast

  • November 2016
    52 pages
  • Cancer  

    Therapy  

  • United States  

View report >

Cancer Statistics in the US

  • October 2016
  • Cancer  

    Leukemia  

    Brain Cancer  

  • United States  

    North America  

View report >

Related Market Segments :

Brain Cancer
Cancer
Therapy
Oncology
Protein

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.